Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Definium Therapeutics, Inc.DFTX · Entity 3884 | Chief Medical Officer | September 14, 2026 | September 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Definium Therapeutics, Inc.
Report date September 14, 2026 · Filed September 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 803,699 |
Reported balance
After 2026-09-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-14 · Grant · Acquired 200,000 · Balance 803,699 F1: The common shares represent the third tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement. F2: Amount includes 417 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan on August 17, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The common shares represent the third tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement.
F2: Amount includes 417 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan on August 17, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 14, 2026 Filed Sep 14, 2026 12:30 UTC | Definium Therapeutics, Inc. DFTX · Entity 3884 | GrantCommon Shares | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-389892 · ownership.xml · nonDerivative · entry 1 Karlin Daniel · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 803,699 F1 · shares: The common shares represent the third tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement. F2 · balance_after: Amount includes 417 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan on August 17, 2026. Read SEC document |
| August 12, 2026 Filed Aug 12, 2026 12:30 UTC | Definium Therapeutics, Inc. DFTX · Entity 3884 | GrantCommon Shares | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-345838 · ownership.xml · nonDerivative · entry 1 Karlin Daniel · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 603,282 F1 · shares: The common shares represent the second tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 20:30 UTC | Definium Therapeutics, Inc. DFTX · Entity 3884 | SaleCommon Shares | 10,035 | $45.03 | $451,876.05 |
DisclosureSEC source: 0001193125-26-285564 · ownership.xml · nonDerivative · entry 1 Karlin Daniel · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 503,282 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 14, 2022. Read SEC document |
| June 22, 2026 Filed Jun 22, 2026 13:45 UTC | Definium Therapeutics, Inc. DFTX · Entity 3884 | GrantCommon Shares | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-276878 · ownership.xml · nonDerivative · entry 1 Karlin Daniel · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 513,317 F1 · shares: The common shares represent the first tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement. Read SEC document |
| March 25, 2026 Filed Mar 26, 2026 22:43 UTC | Definium Therapeutics, Inc. DFTX · Entity 3884 | SaleCommon Shares | 8,018 | $18.47 | $148,092.46 |
DisclosureSEC source: 0001193125-26-126830 · ownership.xml · nonDerivative · entry 1 Karlin Daniel · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 413,317 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 14, 2022. F2 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on March 25, 2026 at prices ranging from $18.36 to $18.80. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Amount includes 1,586 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 21:54 UTC | Definium Therapeutics, Inc. DFTX · Entity 3884 | GrantCommon Shares | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-039576 · ownership.xml · nonDerivative · entry 1 Karlin Daniel · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 575,025 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
| December 26, 2025 Filed Dec 29, 2025 22:00 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 5,600 | $13.15 | $73,622.64 |
DisclosureSEC source: 0001193125-25-335484 · ownership.xml · nonDerivative · entry 1 Karlin Daniel · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 425,025 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 14, 2022. F2 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on December 26, 2025 at prices ranging from $13.02 to $13.33. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 25, 2025 Filed Sep 26, 2025 21:34 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 7,704 | $9.77 | $75,268.08 |
DisclosureSEC source: 0001193125-25-220843 · ownership.xml · nonDerivative · entry 1 Karlin Daniel · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 430,625 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 14, 2022. Read SEC document |
| June 25, 2025 Filed Jun 26, 2025 20:30 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 7,848 | $6.80 | $53,366.40 |
DisclosureSEC source: 0000950170-25-090429 · ownership.xml · nonDerivative · entry 1 Karlin Daniel · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 438,329 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 14, 2022. F2 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on June 25, 2025 at prices ranging from $6.67 to $7.03. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 25, 2025 Filed Mar 26, 2025 21:00 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 6,836 | $6.74 | $46,074.64 |
DisclosureSEC source: 0000950170-25-045396 · ownership.xml · nonDerivative · entry 1 Karlin Daniel · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 446,177 F1 · shares: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 14, 2022. F2 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on March 25, 2025 at prices ranging from $6.67 to $6.79. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 12, 2025 Filed Mar 13, 2025 20:30 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantCommon Shares | 115,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-038800 · ownership.xml · nonDerivative · entry 1 Karlin Daniel · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 453,013 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
| December 26, 2024 Filed Dec 27, 2024 21:30 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 6,643 | $7.43 | $49,357.49 |
DisclosureSEC source: 0001104659-24-132164 · tm2432133-2_4seq1.xml · nonDerivative · entry 1 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 338,013 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 14, 2022. F2 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on December 26, 2024 at prices ranging from $6.98 to $7.66. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 25, 2024 Filed Sep 26, 2024 00:29 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 6,871 | $5.98 | $41,088.58 |
DisclosureSEC source: 0000950170-24-109448 · ownership.xml · nonDerivative · entry 1 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 344,656 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 14, 2022. F2 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on September 25, 2024 at prices ranging from $5.95 to $6.07. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 25, 2024 Filed Jun 25, 2024 23:00 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 6,925 | $7.22 | $49,998.50 |
DisclosureSEC source: 0000950170-24-077496 · ownership.xml · nonDerivative · entry 1 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 351,527 F1 · shares: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 14, 2022. F2 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on June 25, 2024 at prices ranging from $7.20 to $7.26. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 25, 2024 Filed Mar 26, 2024 21:15 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 6,578 | $9.50 | $62,491.00 |
DisclosureSEC source: 0000950170-24-036573 · ownership.xml · nonDerivative · entry 1 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 358,452 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 14, 2022. F2 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on March 25, 2024 at prices ranging from $9.37 to $9.55. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:45 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0000950170-24-023200 · ownership.xml · derivative · entry 1 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Shares · 150,000 shares Expires 2034-02-26 F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in 48 equal monthly installments, with the first installment vesting on March 27, 2024, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date. Read SEC document |
| December 26, 2023 Filed Dec 26, 2023 21:59 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 6,774 | $3.63 | $24,589.62 |
DisclosureSEC source: 0000950170-23-073078 · ownership.xml · nonDerivative · entry 1 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 365,030 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections. F2 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on December 26, 2023 at prices ranging from $3.60 to $3.67 US Dollars. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 25, 2023 Filed Sep 26, 2023 01:30 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 3,240 | $3.58 | $11,599.20 |
DisclosureSEC source: 0000950170-23-049778 · ownership.xml · nonDerivative · entry 2 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 371,804 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections. F3 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on September 25, 2023 at prices ranging from $3.57 to $3.60 US Dollars. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 25, 2023 Filed Sep 26, 2023 01:30 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 3,678 | $3.57 | $13,130.46 |
DisclosureSEC source: 0000950170-23-049778 · ownership.xml · nonDerivative · entry 1 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,044 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections. F2 · price: The reported price is a weighted average sales price. This represents the price in United States Dollars using the conversion rate on September 25, 2023. These shares were sold in multiple transactions on September 25, 2023 at prices ranging from $4.78 to $4.84 CAD Dollars. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 27, 2023 Filed Jun 27, 2023 23:00 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 2,963 | $3.21 | $9,511.23 |
DisclosureSEC source: 0000950170-23-030247 · ownership.xml · nonDerivative · entry 2 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 378,722 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections. F3 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on June 27, 2023 at prices ranging from $3.20 to $3.23 US Dollars. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 27, 2023 Filed Jun 27, 2023 23:00 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 3,820 | $3.19 | $12,185.80 |
DisclosureSEC source: 0000950170-23-030247 · ownership.xml · nonDerivative · entry 1 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 381,685 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections. F2 · price: The reported price is a weighted average sales price. This represents the price in United States Dollars using the conversion rate on June 27, 2023. These shares were sold in multiple transactions on June 27, 2023 at prices ranging from $4.20 to $4.23 CAD Dollars. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 14, 2023 Filed Mar 17, 2023 22:40 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantCommon Shares | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-019894 · doc4.xml · nonDerivative · entry 1 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,505 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 14, 2023, subject, to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 02:45 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 3,577 | $3.51 | $12,555.27 |
DisclosureSEC source: 0000899243-23-006788 · doc4.xml · nonDerivative · entry 1 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,505 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections. F2 · price: The reported price is a weighted average sales price. This represents the price in United States Dollars using the conversion rate on March 1, 2023. These shares were sold in multiple transactions on March 1, 2023 at prices ranging from $4.75 to $4.80 CAD Dollars. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 21, 2022 Filed Dec 22, 2022 21:32 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 1,211 | $2.69 | $3,257.59 |
DisclosureSEC source: 0000899243-22-039212 · doc4.xml · nonDerivative · entry 1 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,082 F1 · kind: Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on November 24, 2022 and November 26, 2022, pursuant to sell-to-cover elections. F2 · price: The reported price is a weighted average sales price. This represents the price in United States Dollars using the conversion rate on December 21, 2022. These shares were sold in multiple transactions on December 21, 2022 at prices ranging from $3.65 to $3.67 CAD Dollars. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 27, 2022 Filed Oct 27, 2022 21:52 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 644 | $3.00 | $1,932.00 |
DisclosureSEC source: 0000899243-22-034336 · doc4.xml · nonDerivative · entry 2 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,293 F3 · kind: Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on October 26, 2022 pursuant to sell-to-cover elections. F4 · price: The Common Shares were sold in multiple transactions, all at a price of $4.07 CAD Dollars. This represents the price in United States Dollars using the conversion rate on October 27, 2022. Read SEC document |
| October 25, 2022 Filed Oct 27, 2022 21:52 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 541 | $2.81 | $1,520.21 |
DisclosureSEC source: 0000899243-22-034336 · doc4.xml · nonDerivative · entry 1 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,937 F1 · kind: Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on October 24, 2022 pursuant to sell-to-cover elections. F2 · price: The Common Shares were sold in multiple transactions, all at a price of $3.83 CAD Dollars. This represents the price in United States Dollars using the conversion rate on October 25, 2022. Read SEC document |
| September 27, 2022 Filed Sep 28, 2022 00:48 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 640 | $5.87 | $3,756.80 |
DisclosureSEC source: 0000899243-22-032169 · doc4.xml · nonDerivative · entry 2 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,478 F3 · kind: Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on September 26, 2022 pursuant to sell-to-cover elections. F4 · price: The Common Shares were sold in one transaction at a price of $8.06 CAD Dollars. This represents the price in United States Dollars using the conversion rate on September 27, 2022. Read SEC document |
| September 26, 2022 Filed Sep 28, 2022 00:48 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 565 | $5.51 | $3,113.15 |
DisclosureSEC source: 0000899243-22-032169 · doc4.xml · nonDerivative · entry 1 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,118 F1 · kind: Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on September 24, 2022 pursuant to sell-to-cover elections. F2 · price: The Common Shares were sold in one transaction at a price of $7.60 CAD Dollars. This represents the price in United States Dollars using the conversion rate on September 26, 2022. Read SEC document |
| August 31, 2022 Filed Sep 1, 2022 16:24 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 1,204 | $11.67 | $14,050.68 |
DisclosureSEC source: 0000899243-22-030159 · doc4.xml · nonDerivative · entry 1 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,683 F1 · kind: Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on August 24, 2022 and on August 26, 2022 pursuant to sell-to-cover elections. F2 · price: The Common Shares were sold in one transaction at a price of $15.31 CAD Dollars. This represents the price in United States Dollars using the conversion rate on August 31, 2022. F3 · balance_after: On August 26, 2022, the Issuer effected a 1-for-15 reverse stock split (the" Reverse Stock Split"). The number of securities reported on the Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| July 27, 2022 Filed Jul 27, 2022 23:49 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 9,856 | $0.69 | $6,800.64 |
DisclosureSEC source: 0000899243-22-026910 · doc4.xml · nonDerivative · entry 2 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,033,264 F3 · kind: Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on July 26, 2022 pursuant to sell-to-cover elections. F4 · price: The Common Shares were sold in one transaction at a price of $0.89 CAD Dollars. This represents the price in United States Dollars using the conversion rate on July 27, 2022. Read SEC document |
| July 25, 2022 Filed Jul 27, 2022 23:49 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 8,361 | $0.69 | $5,769.09 |
DisclosureSEC source: 0000899243-22-026910 · doc4.xml · nonDerivative · entry 1 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,043,120 F1 · kind: Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on July 24, 2022 pursuant to sell-to-cover elections. F2 · price: The Common Shares were sold in one transaction at a price of $0.88 CAD Dollars. This represents the price in United States Dollars using the conversion rate on July 25, 2022. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 22:04 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 26,238 | $0.70 | $18,366.60 |
DisclosureSEC source: 0000899243-22-024434 · doc4.xml · nonDerivative · entry 1 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,051,481 F1 · kind: Common Shares sold to satisfy withholding tax obligations upon the delivery of Common Shares for restricted stock units that vested on June 24, 2022 and June 26, 2022 pursuant to sell-to-cover elections. F2 · price: The Common Shares were sold in one transaction at a price of $0.90 CAD Dollars. This represents the price in United States Dollars using the conversion rate on June 27, 2022. Read SEC document |
| May 27, 2022 Filed May 31, 2022 22:53 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleSubordinate Voting Shares | 9,555 | $0.82 | $7,835.10 |
DisclosureSEC source: 0001209191-22-032973 · doc4.xml · nonDerivative · entry 1 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,077,719 F1 · kind: Subordinate Voting Shares sold to satisfy withholding tax obligations upon the delivery of Subordinate Voting Shares for restricted stock units that vested on May 26, 2022. F2 · price: The Subordinate Voting Shares were sold in one transaction at a price of $1.05 CAD dollars to cover payroll taxes. This represents the price in U.S. Dollars using the conversion rate on May 27, 2022. Read SEC document |
| May 25, 2022 Filed May 27, 2022 01:08 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleSubordinate Voting Shares | 8,242 | $0.77 | $6,346.34 |
DisclosureSEC source: 0001209191-22-032382 · doc4.xml · nonDerivative · entry 1 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,087,274 F1 · kind: Subordinate Voting Shares sold to satisfy withholding tax obligations upon the delivery of Subordinate Voting Shares for restricted stock units that vested on May 24, 2022. F2 · price: The Subordinate Voting Shares were sold in one transaction at a price of $0.99 CAD dollars. This represents the price in U.S. Dollars using the conversion rate on May 25, 2022. Read SEC document |
| April 26, 2022 Filed Apr 27, 2022 21:09 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | Tax withholdingSubordinate Voting Shares | 13,038 | $0.81 | $10,560.78 |
DisclosureSEC source: 0001209191-22-025810 · doc4.xml · nonDerivative · entry 1 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,095,516 F1 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of 23,541 restricted stock units. F2 · price: The closing price of our Subordinate Voting Shares as of April 26, 2022 on the NEO was $1.04 Canadian Dollars. This represents the price in United States Dollars. Read SEC document |
| March 28, 2022 Filed Mar 30, 2022 01:39 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | Tax withholdingSubordinate Voting Shares | 10,203 | $1.17 | $11,937.51 |
DisclosureSEC source: 0001209191-22-021558 · doc4.xml · nonDerivative · entry 1 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,108,554 F1 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of 23,541 restricted stock units ("RSUs"). F2 · price: The closing price of our Subordinate Voting Shares as of March 28, 2022 on the NEO was $1.46 Canadian Dollars. This represents the price in United States Dollars. Read SEC document |
| March 24, 2022 Filed Mar 29, 2022 00:11 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantStock Option (Right to Buy) · Derivative | 1,250,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001209191-22-021387 · doc4.xml · derivative · entry 2 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,719,000 Underlying: Subordinate Voting Shares · 1,250,000 shares Expires 2027-03-23 F2 · derivative.exercise_price: The option grant has an exercise price of $1.48 Canadian Dollars. This represents the exercise price in United States Dollars. F3 · derivative.exercise_date: The shares subject to the option vest and become exercisable with 1/48th of the total shares vesting monthly over 48 months from the vesting commencement date, March 24, 2022, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date. Read SEC document |
| March 24, 2022 Filed Mar 29, 2022 00:11 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantSubordinate Voting Shares | 950,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021387 · doc4.xml · nonDerivative · entry 1 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,118,757 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one subordinate voting share of the Issuer. The RSUs vest in 48 equal monthly installments beginning on April 24, 2022, subject, to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 23:32 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | Tax withholdingSubordinate Voting Shares | 118,143 | $1.21 | $142,953.03 |
DisclosureSEC source: 0001209191-22-014338 · doc4.xml · nonDerivative · entry 1 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,168,757 F1 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of 282,500 restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.